IMPUTE Inc. Announces Investment by i-nest capital to Accelerate Growth.
IMPUTE, Inc., a Tokyo based company, has announced a 150 million JPY (1.3 million USD) investment in its Series A funding by i-nest capital, a Tokyo-based venture capital firm.
IMPUTE was founded by Dr. Mayank Singh for the purpose of developing digital therapeutics for the autism spectrum disorder. The company is developing an application that uses AI technology and applied behavior analysis to treat and alleviate the symptoms of ASD. Applied Behavior Analysis (ABA) is an established intervention method to treat or alleviate ASD symptoms. IMPUTE will use the funds to expedite development of the app and for clinical trials.
i-nest capital was founded in 2019 and is headed by Mr. Takashi Yamanaka. Dr. Singh has expressed his gratitude to Mr. Yamanaka and the i-nest team for understanding IMPUTE’s vision and for their trust in the IMPUTE team. He has also expressed his gratitude to Mr. Toshihiko Honkura, a partner in i-nest capital, for making the investment process smooth and for his understanding of the niche area that digital therapeutics for ASD holds. Mr. Honkura will be appointed as external board member of IMPUTE Inc. Below is the link for the i-nest capital press release regarding the investment.
Below is the link for the i-nest capital press release regarding the investment.
Article in Nikkei BP about IMPUTE efforts and its goal for Autism.
Impute recently raised a pre-series A round from TEP (Tx Entrepreneurs Partners), Arco Partners and other angel investors.
IMPUTE has started clinical research on Autism therapy app for autism spectrum disorders at the National Center for Child Health and Development, Japan. Children aged between 18 months to 6 years who have been diagnosed with autism spectrum disorder or who are suspected of having autism spectrum disorder and are consulted with a counseling agency are eligible. Click the links below to view the patient recruitment and detailed application form. Feel free to contact us with any questions or enrollment in the study – email@example.com